18,505 Shares in Revolution Medicines, Inc. $RVMD Purchased by CW Advisors LLC

Key Points

• CW Advisors LLC acquired 18,505 shares of Revolution Medicines, Inc. for approximately $654,000 as part of their first quarter investments.
• Revolution Medicines reported a quarterly earnings per share (EPS) of ($1.31), which was below analysts' expectations of ($0.94).
• Thirteen research analysts have rated Revolution Medicines as a "Buy," with an average price target of $69.92 for the stock.

CW Advisors LLC acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,505 shares of the company's stock, valued at approximately $654,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kapitalo Investimentos Ltda acquired a new stake in Revolution Medicines during the fourth quarter worth about $104,000. GF Fund Management CO. LTD. acquired a new stake in Revolution Medicines during the fourth quarter worth about $154,000. Goodman Advisory Group LLC purchased a new position in Revolution Medicines during the first quarter worth about $127,000. PNC Financial Services Group Inc. boosted its stake in Revolution Medicines by 349.7% during the first quarter. PNC Financial Services Group Inc. now owns 4,524 shares of the company's stock worth $160,000 after buying an additional 3,518 shares during the period. Finally, Sandia Investment Management LP purchased a new position in Revolution Medicines during the fourth quarter worth about $219,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Stock Up 4.5%

Shares of Revolution Medicines stock opened at $37.28 on Wednesday. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40. The company has a 50 day moving average of $37.36 and a 200 day moving average of $38.26. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $6.97 billion, a P/E ratio of -8.28 and a beta of 1.16.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). During the same period in the prior year, the firm posted ($0.81) EPS. The business's quarterly revenue was up .0% compared to the same quarter last year. As a group, research analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on RVMD. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price (down previously from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $73.00 target price (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. Wells Fargo & Company began coverage on shares of Revolution Medicines in a research note on Friday, August 15th. They set an "overweight" rating and a $67.00 target price for the company. Needham & Company LLC lowered their target price on shares of Revolution Medicines from $57.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, Guggenheim reaffirmed a "buy" rating and set a $80.00 target price on shares of Revolution Medicines in a research note on Wednesday, June 25th. Thirteen equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Revolution Medicines has an average rating of "Buy" and an average price target of $69.92.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.